Daré Bioscience(DARE)
$0.69+0.01 (+8.29%)
DARE
Daré Bioscience financials statements
$0.69
At close:+0.01 (+8.29%)
Want to see DARE full AI Analyst Report?
Daré Bioscience (DARE) Ratios
1,905 Followers
Daré Bioscience Ratios
DARE's free cash flow for Q2 2026 was $-6.86M. For the 2026 fiscal year, DARE's free cash flow was decreased by $-80.59K and operating cash flow was $-6.78M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Mar 25 | Dec 23 | Dec 22 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.14 | 0.85 | 0.86 | 1.36 | 3.44 |
| Quick Ratio | 1.14 | 0.85 | 0.86 | 1.36 | 3.44 |
| Cash Ratio | 1.04 | 0.73 | 0.51 | 1.10 | 3.22 |
| Solvency Ratio | -0.38 | -0.14 | -1.14 | -0.95 | -2.27 |
| Operating Cash Flow Ratio | -0.42 | 0.25 | -1.90 | -0.57 | -1.79 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ -2.57M | $ -9.67M | $ -8.79M | $ 10.32M | $ 38.24M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.08 | 0.06 | 0.07 | 0.01 | 0.00 |
| Debt-to-Equity Ratio | 0.93 | -0.22 | -0.28 | 0.04 | 0.01 |
| Debt-to-Capital Ratio | 0.48 | -0.28 | -0.39 | 0.04 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 11.42 | -3.68 | -4.22 | 3.94 | 1.44 |
| Debt Service Coverage Ratio | -12.67 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | -16.47 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.03 | 0.15 | 0.19 | 0.07 | 0.05 |
| Net Debt to EBITDA | 2.12 | 3.59 | 0.30 | 1.09 | 1.32 |
| Profitability Margins | |||||
| Gross Profit Margin | -137.55% | -146110.22% | -670.62% | -201.42% | 0.00% |
| EBIT Margin | -1220.80% | -41430.90% | -1094.77% | -313.85% | 0.00% |
| EBITDA Margin | -1011.96% | -40998.30% | -1093.40% | -313.61% | 0.00% |
| Operating Profit Margin | -1315.51% | -239692.20% | -1101.89% | -313.85% | 0.00% |
| Pretax Profit Margin | -1300.66% | -41430.90% | -1074.17% | -309.48% | 0.00% |
| Net Profit Margin | -1300.66% | -41430.90% | -1074.17% | -309.48% | 0.00% |
| Continuous Operations Profit Margin | -1300.66% | -41430.90% | -1074.17% | -309.48% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 98.87% | 17.29% | 97.48% | 98.61% | 99.05% |
| Return on Assets (ROA) | -41.26% | -18.34% | -141.72% | -70.61% | -69.34% |
| Return on Equity (ROE) | -471.37% | 67.42% | 597.53% | -278.50% | -99.85% |
| Return on Capital Employed (ROCE) | -154.20% | -4765.42% | -3858.90% | -257.21% | -98.27% |
| Return on Invested Capital (ROIC) | -124.50% | -2253.31% | -2435.24% | -249.07% | -97.61% |
| Return on Tangible Assets | -41.26% | -18.34% | -141.72% | -70.61% | -69.34% |
| Earnings Yield | -6.21% | -15.29% | -104.96% | -44.09% | -31.64% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.80 | 0.04 | 2.96 | 5.87 | 0.00 |
| Payables Turnover | 2.04 | 9.83 | 6.39 | 14.86 | 0.05 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.23 | 0.00 | 1.42 | 19.13 | 0.00 |
| Asset Turnover | 0.03 | 0.00 | 0.13 | 0.23 | 0.00 |
| Working Capital Turnover Ratio | 9.49 | -0.00 | 0.66 | 0.39 | 0.00 |
| Cash Conversion Cycle | 23.95 | 8542.52 | 66.28 | 37.61 | -7676.25 |
| Days of Sales Outstanding | 203.04 | 8579.66 | 123.39 | 62.17 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 179.08 | 37.15 | 57.11 | 24.56 | 7676.25 |
| Operating Cycle | 203.04 | 8579.66 | 123.39 | 62.17 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.09 | 0.63 | -5.34 | -2.57 | -5.64 |
| Free Cash Flow Per Share | -0.09 | 0.57 | -5.43 | -2.58 | -5.65 |
| Dividend Paid and CapEx Coverage Ratio | -25.66 | 9.41 | -61.73 | -286.80 | -1980.45 |
| Capital Expenditure Coverage Ratio | -25.66 | 9.41 | -61.73 | -286.80 | -1980.45 |
| Operating Cash Flow Coverage Ratio | -3.72 | 4.14 | -27.67 | -37.01 | -106.32 |
| Operating Cash Flow to Sales Ratio | -9.60 | 551.33 | -13.84 | -1.81 | 0.00 |
| Free Cash Flow Yield | -4.76% | 18.19% | -137.41% | -25.86% | -23.53% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.61 | -6.54 | -0.95 | -2.27 | -3.16 |
| Price-to-Sales (P/S) Ratio | 209.43 | 2709.59 | 10.23 | 7.02 | 0.00 |
| Price-to-Book (P/B) Ratio | 75.90 | -4.41 | -5.69 | 6.32 | 3.16 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -21.01 | 5.50 | -0.73 | -3.87 | -4.25 |
| Price-to-Operating Cash Flow Ratio | -21.82 | 4.91 | -0.74 | -3.88 | -4.25 |
| Price-to-Earnings Growth (PEG) Ratio | -0.01 | 0.07 | 0.17 | 0.05 | 0.10 |
| Enterprise Value Multiple | -18.58 | -3.02 | -0.64 | -1.15 | -1.82 |
| Enterprise Value | 193.69M | 12.12M | 19.66M | 36.02M | 70.90M |
| EV to EBITDA | -18.58 | -3.02 | -0.64 | -1.15 | -1.82 |
| EV to Sales | 188.02 | 1238.30 | 7.00 | 3.60 | 0.00 |
| EV to Free Cash Flow | -18.86 | 2.51 | -0.50 | -1.98 | -2.46 |
| EV to Operating Cash Flow | -19.59 | 2.25 | -0.51 | -1.99 | -2.46 |
| Tangible Book Value Per Share | 0.03 | -0.71 | -0.69 | 1.58 | 7.60 |
| Shareholders’ Equity Per Share | 0.03 | -0.71 | -0.69 | 1.58 | 7.60 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.01 | 0.00 | 0.39 | 1.42 | 0.00 |
| Net Income Per Share | -0.12 | -0.48 | -4.15 | -4.39 | -7.59 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.07 | 1.00 | 0.98 | 0.99 | 0.99 |
| Research & Development to Revenue | 5361.47 | 1451.88 | 7.67 | 3.00 | 0.00 |
| SG&A to Revenue | 8.51 | 935.82 | 4.03 | 1.06 | 0.00 |
| Stock-Based Compensation to Revenue | 1.45 | 225.19 | 0.90 | 0.22 | 0.00 |
| Income Quality | 0.74 | -1.33 | 1.29 | 0.58 | 0.74 |
Currency in USD
